Cited by 29Mangiferin and Mango ExtractsDrug Solubulity and Delivery SystemsPharmacology and Nanomedicine Research

Recent Formulation Advances of Mangiferin

Open access
Barakat, Sara, Nasr, Maha, Ahmed, Rania F., Badawy, Sabry, Mortada, Nahed·2022·Revista Brasileira de Farmacognosia

Abstract

Nutraceuticals have recently gained interest owing to their valuable contribution in the treatment of several diseases, with high safety margin and low incidence of side effects. However, their efficacy is limited by some challenges, namely poor solubility, low permeability, and, consequently, low bioavailability. Delivery carriers have proven that they can overcome almost all the aforementioned limitations, leading to improvement in the pharmacological efficacy of nutraceuticals. Among the promising nutraceuticals that have currently evoked considerable interest is mangiferin from mango tree, which is a polyphenol exhibiting many favorable pharmacological actions, but unfortunately suffers from poor aqueous solubility and other limitations that lower its bioavailability and halter its efficacy. This review summarizes the pharmacological actions of mangiferin and provides an insight on how delivery carriers for mangiferin (lipidic, vesicular, polymeric, inorganic, and protein nanoparticles, as well as complexes) can overcome its pharmaceutical challenges, hence reflecting on its improved therapeutic effects in treatment of different diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s43450-022-00297-z

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • After uptake in the proximal small intestine, extensive first-pass metabolism and gut microbiota-mediated deglycosylation reduce parent MGF levels.

    “After uptake in the proximal small intestine, extensive first-pass metabolism and gut microbiota-mediated deglycosylation (yielding norathyriol and downstream conjugates) further reduce parent drug levels (21,160-162).”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [161]

    The Bioavailability section reports greater mangiferin absorption in the duodenum and jejunum than farther along the intestine, and intensive hepatic first-pass metabolism that reduces the dose reaching circulation in normal rats. The Metabolism section describes deglycosylation to norathyriol followed by gut-microbiome-mediated conjugation, but does not specifically attribute the deglycosylation step to the microbiota. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Material standardization is uneven, with frequent use of extracts or nanoparticles without full reporting of purity, content uniformity, or release profiles.

    “Material standardization is uneven, with frequent use of extracts or nanoparticles without full reporting of purity, content uniformity or release profiles, making cross-study comparisons difficult and weakening conclusions regarding the active entity (161,181).”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [161]

    The Protein Nanoparticles section (page unavailable) notes poor reproducibility and batch-to-batch variation, and the review discusses mangiferin nanoparticle formulations. It does not establish that studies frequently omit purity, content-uniformity or release-profile reporting, or that such omissions impede cross-study comparisons. (LLM, conf=0.79)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Barakat, S., Nasr, M., Ahmed, R. F., Badawy, S., & Mortada, N.
Affiliations
  • Misr International University (EG)
  • Ain Shams University (EG)
  • National Research Centre (EG)
Corresponding author
Nasr, Maha
Venue
Revista Brasileira de Farmacognosia
Published
2022-10-04
Volume
32
Issue
6
Pages
871-882
ISSN
  • 0102-695X (ISSN-L)
  • 1981-528X
OpenAlex
W4301394388
Cited by
28
References
113
Citations by year
2026: 4 · 2025: 10 · 2024: 9 · 2023: 5
FWCI
6.25
Type
journal article
Language
en
Open access
Locations
Revista Brasileira de Farmacognosia (publishedVersion, cc-by)
Funders
Ain Shams University
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
Keywords
mangiferin, nutraceuticals, bioavailability enhancement, water solubility, drug carriers, nanoparticles, liposomes, polymeric nanoparticles, inorganic nanoparticles, protein nanoparticles, pharmacological activity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review